US Stock Movement: Capricor surges on September 30th driven by HOPE-3 data and FDA review

Capricor September 30 Surge Analysis

Keywords: HOPE-3 data, FDA review

1. On September 29, the HOPE-3 open-label extension data for Deramiocel was presented at the World Muscle Society Congress; after switching from placebo to Deramiocel, the decline rate in patients' upper limb function decreased from 2.05 points to 0.49 points, a 76% reduction, and the decline in elbow function decreased from 1.33 points to 0.45 points, a 66% reduction.

2. On September 29, the company disclosed that out of 106 randomized patients in HOPE-3, 82 reached the 24-month observation point. The relevant 24-month skeletal muscle and cardiac outcome data support its regulatory application for the Duchenne Muscular Dystrophy cell therapy, Deramiocel; the FDA target action date is November 22.

(Disclaimer: This content is generated by AI technology through summarizing publicly available information, for reference only and does not constitute investment advice.)